Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 8, 2005, Pages 969-975

  Todd, J A ^a   Basu, K K ^b   De Caestecker, J S ^a,c  

^a UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

^c LEICESTER GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ARGON PLASMA COAGULATION; ARTICLE; BARRETT ESOPHAGUS; CLINICAL ARTICLE; DRUG EFFICACY; DUODENOGASTRIC REFLUX; ESOPHAGUS PH; ESOPHAGUS PRESSURE; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MALE; PATHOPHYSIOLOGY; PRESSURE MEASUREMENT; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; DUODENAL DISEASES; ESOPHAGOSCOPY; ESOPHAGUS; FEMALE; GASTRIC ACID; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS;

EID: 17244372170     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02406.x     Document Type: Article

References (60)

1. Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997: 112: 1448-56.
2. Robertson D, Aldersley M, Shepherd H, Smith CL. Patterns of acid reflux in complicated oesophagitis. Gut 1987; 28: 1484-8.
3. Gotley DC, Morgan AP, Ball D, Owen RW, Cooper MJ. Composition of gastro-oesophageal refluxate. Gut 1991; 32: 1093-9.
4. Iftikhar SY, Ledingham S, Steele RJ, et al. Bile reflux in columnar-lined Barrett's oesophagus. Ann R Coll Surg Engl 1993; 75: 411-6.
5. Nehra D, Howell P, Pye JK, Beynon J. Assessment of combined bile acid and pH profiles using an automated sampling device in gastro-oesophageal reflux disease. Br J Surg 1998; 85: 134-7.
6. Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 1999; 44: 598-602.
7. Iascone C, DeMeester TR, Little AG, Skinner DB. Barrett's esophagus. Functional assessment, proposed pathogenesis, and surgical therapy. Arch Surg 1983; 118: 543-9.
8. Champion G, Richter JE, Vaezi MF, Singh S, Alexander R. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994; 107: 747-54.
9. Kauer WK, Burdiles P, Ireland AP, et al. Does duodenal juice reflux into the esophagus of patients with complicated GERD? Evaluation of a fiberoptic sensor for bilirubin. Am J Surg 1995; 169: 98-103.
10. Vaezi MF, Richter JE. Synergism of acid and duodenogastroesophageal reflux in complicated Barrett's esophagus. Surgery 1995; 117: 699-704.
11. Caldwell MT, Lawlor P, Byrne PJ, Walsh TN, Hennessy TP. Ambulatory oesophageal bile reflux monitoring in Barrett's oesophagus. Br J Surg 1995; 82: 657-60.
12. Jankowski J, Harrison RF, Perry I, Balkwill F, Tselepis C. Seminar: Barrett's metaplasia. Lancet 2000; 356: 2079-85.
13. Marshall RE, Anggiansah A, Manifold DK, Owen WA, Owen WJ. Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus. Gut 1998; 43: 603-6.
14. Wilmer A, Tack J, Frans E, et al. Duodenogastroesophageal reflux and esophageal mucosal injury in mechanically ventilated patients. Gastroenterology 1999; 116: 1293-9.
15. Stein HJ, Kauer WK, Feussner H, Siewert JR. Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and Nissen fundoplication. J Gastrointest Surg 1998; 2: 333-41.
16. Sarela AI, Hick DG, Verbeke CS, Casey JF, Guillou PJ, Clark GW. Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy. Arch Surg 2004; 139: 547-51.
17. Marcus G. Gastroesophageal reflux and adenocarcinoma of the esophagus. N Engl J Med 1999; 341: 537-8.
18. Basu KK, Pick B, Bale R, West KP, de Caestecker JS. Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium. Gut 2002; 51: 776-80.
19. McClave SA, Boyce HW Jr, Gottfried MR. Early diagnosis of columnar-lined esophagus: a new endoscopic diagnostic criterion. Gastrointest Endosc 1987; 33: 413-6.
20. Bechi P, Pucciani F, Baldini F, et al. Long-term ambulatory enterogastric reflux monitoring. Validation of a new fiberoptic technique. Dig Dis Sci 1993; 38: 1297-306.
21. Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: effects on gastric acid and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996; 91: 1532-8.
22. Castell DO. Omeprazole works best when used properly. Eur J Gastroenterol Hepatol 1996; 8: 413-4.
23. Vaezi MF, Lacamera RG, Richter JE. Validation studies of Bilitec 2000: an ambulatory duodenogastric reflux monitoring system. Am J Physiol 1994; 267: G1050-7.
24. Basu K, Bale R, West K, de Caestecker JS. The effects of argon plasma coagulation therapy for Barrett's epithelium on oesophageal motility. Gut 2000; 47 (Suppl. III): A66 (abstract P62).
25. Gillison EW, De Castro VA, Nyhus LM, Kusakari K, Bombeck CT. The significance of bile in reflux esophagitis. Surg Gynecol Obstet 1972; 134: 419-24.
26. Salo JA, Kivilaakso E. Role of bile salts and trypsin in the pathogenesis of experimental alkaline esophagitis. Surgery 1983; 93: 525-32.
27. Lillemoe KD, Johnson LF, Harmon JW. Taurodeoxycholate modulates the effects of pepsin and trypsin in experimental esophagitis. Surgery 1985; 97: 662-7.
28. Harmon JW, Johnson LF, Maydonovitch CL. Effects of acid and bile salts on the rabbit esophageal mucosa. Dig Dis Sci 1981; 26: 65-72.
29. Kivilaakso E, Fromm D, Silen W. Effect of bile salts and related compounds on isolated esophageal mucosa. Surgery 1980; 87: 280-5.
30. Salo J, Kivilaakso E. Role of luminal H+ in the pathogenesis of experimental esophagitis. Surgery 1982; 92: 61-8.
31. Lillemoe KD, Johnson LF, Harmon JW. Alkaline esophagitis: a comparison of the ability of components of gastroduodenal contents to injure the rabbit esophagus. Gastroenterology 1983; 85: 621-8.
32. Lillemoe KD, Johnson LF, Harmon JW. Role of the components of the gastroduodenal contents in experimental acid esophagitis. Surgery 1982; 92: 276-84.
33. Hopwood D, Bateson MC, Milne G, Bouchier IA. Effects of bile acids and hydrogen ion on the fine structure of oesophageal epithelium. Gut 1981; 22: 306-11.
34. Bateson MC, Hopwood D, Milne G, Bouchier IA. Oesophageal epithelial ultrastructure after incubation with gastrointestinal fluids and their components. J Pathol 1981; 133: 33-51.
35. Pera M, Cardesa A, Bombi JA, Ernst H, Pera C, Mohr U. Influence of esophagojejunostomy on the induction of adenocarcinoma of the distal esophagus in Sprague-Dawley rats by subcutaneous injection of 2,6- dimethylnitrosomorpholine. Cancer Res 1989; 49: 6803-8.
36. Attwood SE, Smyrk TC, DeMeester TR, Mirvish SS, Stein HJ, Hinder RA. Duodenoesophageal reflux and the development of esophageal adenocarcinoma in rats. Surgery 1992; 111: 503-10.
37. Ireland AP, Peters JH, Smyrk TC, et al. Gastric juice protects against the development of esophageal adenocarcinoma in the rat. Ann Surg 1996; 224: 358-70.
38. Snepar R, Poporad GA, Romano JM, Kobasa WD, Kaye D. Effect of cimetidine and antacid on gastric microbial flora. Infect Immun 1982; 36: 518-24.
39. Ruddell WS, Axon AT, Findlay JM, Bartholomew BA, Hill MJ. Effect of cimetidine on the gastric bacterial flora. Lancet 1980; 1: 672-4.
40. Sharma BK, Santana IA, Wood EC, et al. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. Br Med J (Clin Res Ed) 1984; 289: 717-9.
41. Verdu E, Viani F, Armstrong D, et al. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut 1994; 35: 455-60.
42. Karmeli Y, Stalnikowitz R, Eliakim R, Rahav G. Conventional dose of omeprazole alters gastric flora. Dig Dis Sci 1995; 40: 2070-3.
43. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996; 39: 54-9.
44. Shindo K, Fukushima K. Deconjugation of bile acids by human intestinal bacteria. Gastroenterol Jpn 1976; 11: 167-74.
45. Shindo K, Yamazaki R, Koide K, Fukumura M, Hirai Y. Alteration of bile acid metabolism by cimetidine in healthy humans. J Investig Med 1996; 44: 462-9.
46. Shindo K, Machida M, Fukumura M, Koide K, Yamazaki R. Omeprazole induces altered bile acid metabolism. Gut 1998; 42: 266-71.
47. DeMeester TR. Management of Barrett's esophagus free of dysplasia. Semin Thorac Cardiovasc Surg 1997; 9: 279-84.
48. Attwood SE, DeMeester TR, Bremner CG, Barlow AP, Hinder RA. Alkaline gastroesophageal reflux: implications in the development of complications in Barrett's columnar-lined lower esophagus. Surgery 1989; 106: 764-70.
49. Kauer WK, Peters JH, DeMeester TR, Ireland AP, Bremner CG, Hagen JA. Mixed reflux of gastric and duodenal juices is more harmful to the esophagus than gastric juice alone. The need for surgical therapy re-emphasized. Ann Surg 1995; 222: 525-31.
50. Fioretti F, Tavani A, La Vecchia C, Franceschi S. Histamine-2-receptor antagonists and oesophageal cancer. Eur J Cancer Prev 1997; 6: 143-6.
51. Colin-Jones DG, Langman MJ, Lawson DH, Logan RF, Paterson KR, Vessey MP. Post-cimetidine surveillance for up to ten years: incidence of carcinoma of the stomach and oesophagus. Q J Med 1991; 78: 13-9.
52. Moller H, Lindvig K, Klefter R, Mosbech J, Moller JO. Cancer occurrence in a cohort of patients treated with cimetidine. Gut 1989; 30: 1558-62.
53. Birgisson S, Rice TW, Easley KA, Richter JE. The lack of association between adenocarcinoma of the esophagus and gastric surgery: a retrospective study. Am J Gastroenterol 1997; 92: 216-21.
54. Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF Jr. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995; 274: 474-7.
55. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
56. Parrilla P, Liron R, Martinez de Haro LF, Ortiz A, Molina J, De Andres B. Gastric surgery does not increase the risk of developing Barrett's esophagus. Am J Gastroenterol 1997; 92: 960-3.
57. El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004; 99: 1877-83.
58. Schell TG. Acid suppression and adenocarcinoma of the esophagus: cause or cure? Am J Gastroenterol 2004; 99: 1884-6.
59. Shay S, Tutuian R. Sifrim D, Vela M, Zhang X, Castell D. Twenty four hour impedance and pH monitoring (24-hr Imp-pH) in the evaluation of GERD patients with persistent symptoms despite bid proton pump inhibitors (PPI): a multicentre study. Gastroenterology 2004; 126: A324 (abstract M1392).
60. Sears RJ, Champion G, Richter JE. Characteristics of partial gastrectomy (PG) patients with esophageal symptoms of duodenogastric reflux. Am J Gastroenterol 1995; 90: 211-5.